EP Patent

EP3858993A1 — Compositions and methods for treating duchenne muscular dystrophy and related disorders

Assigned to Sarepta Therapeutics Inc · Expires 2021-08-04 · 5y expired

What this patent protects

The present disclosure relates to compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders. Modified antisense oligomers are disclosed for the treatment of Duchenne muscular dystrophy and related disorders.

USPTO Abstract

The present disclosure relates to compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders. Modified antisense oligomers are disclosed for the treatment of Duchenne muscular dystrophy and related disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3858993A1
Jurisdiction
EP
Classification
—
Expires
2021-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.